surmount-1 tirzepatide non-diabetic obesity trial surmount trials For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults SURMOUNT-5 Trial Effect of tirzepatide in SURMOUNT-1

Side effects are similar to other GLP-1 medications

Each additional receptor target has produced incrementally better results in trials, though no direct head-to-head studies exist yet

Zinc deficiencies, which are very common, lead to increased copper levels, as well as low ceruloplasmin, all of which translates into elevated 'free copper'

After removing the REWIND trial and the POINEER-6 trial respectively, the pooling effect of dulaglutide and oral semaglutide on the risk of AF would lose statistical significance (Additional file 1: Fig

Clinical considerations for dose escalation: The gradual dose titration schedule is designed to minimize gastrointestinal adverse effects, which are the most commonly reported side effects of tirzepatide

A: Results vary by individual, but clinical trials have shown many patients lose a meaningful percentage of their starting body weight over time